Jubilant Life Sciences was locked in an upper circuit of 5% at Rs 426, rising for fifth consecutive session.
The pharma company has gained 27.07% in last five trading sessions from its previous closing low of Rs 335.25 hit on 21 April 2020. The stock has hit an upper circuit of 5% for fifth straight session.The recent rally was triggered by ace investor Rakesh Jhunjhunwala purchasing an additional 0.96% stake in the company in Q4 March 2020.
As per the latest shareholding disclosure, Rakesh Radheshyam Jhunjhunwala hiked his stake in Jubilant Life Sciences to 4.41% in Q4 March 2020, from 3.45% stake held in Q3 December 2019.
Earlier this month, the company announced that its solid dosage facility at Salisbury, Maryland, USA received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the US drug regulator.
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients and other businesses including drug discovery solutions.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
